Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 947

The DOI matches its Crossref record; 357 of the 357 references it cites were found in a registry or an index.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary

Whelton, Paul K., Carey, Robert M., Aronow, Wilbert S., Casey, Donald E., Collins, Karen J., Dennison Himmelfarb, Cheryl, DePalma, Sondra M., Gidding, Samuel, Jamerson, Kenneth A., Jones, Daniel W., MacLaughlin, Eric J., Muntner, Paul, Ovbiagele, Bruce, Smith, Sidney C., Spencer, Crystal C., Stafford, Randall S., Taler, Sandra J., Thomas, Randal J., Williams, Kim A., Williamson, Jeff D., Wright, Jackson T. · 2018 · Journal of the American Society of Hypertension

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jash.2018.06.010

Cites

357 of 357 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 77

  1. Whelton, 2018, Circulation, 71, e13
  2. Gibbons, 2013, The next steps in developing clinical practice guidelines for prevention, Circulation, 128, 1716, 10.1161/CIRCULATIONAHA.113.005548 · DOI
  3. Gibbons, 2013, Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute, Circulation, 128, 1713, 10.1161/CIRCULATIONAHA.113.004587 · DOI
  4. 2013, Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
  5. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  6. Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1 · DOI · Paper page
  7. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  8. Rapsomaniki, 2014, Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people, Lancet, 383, 1899, 10.1016/S0140-6736(14)60685-1 · DOI · Paper page
  9. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  10. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  11. Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141 · DOI · Paper page
  12. Funder, 2016, The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 101, 1889, 10.1210/jc.2015-4061 · DOI · Paper page
  13. Lenders, 2014, Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 99, 1915, 10.1210/jc.2014-1498 · DOI · Paper page
  14. Cortese, 2013, Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol, Psychiatry, 54, 227
  15. Willey, 2014, Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study, J Am Heart Assoc, 3
  16. Mancia, 2013, 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J, 34, 2159, 10.1093/eurheartj/eht151 · DOI · Paper page
  17. Appel, 2003, Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial, JAMA, 289, 2083
  18. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  19. Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, 10.1136/bmj.b1665 · DOI · Paper page
  20. Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8 · DOI · Paper page
  21. Sundstrom, 2014, Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data, Lancet, 384, 591, 10.1016/S0140-6736(14)61212-5 · DOI · Paper page
  22. Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials, J Hypertens, 32, 2296, 10.1097/HJH.0000000000000379 · DOI · Paper page
  23. Sundstrom, 2015, Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis, Ann Intern Med, 162, 184, 10.7326/M14-0773 · DOI · Paper page
  24. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  25. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  26. van Dieren, 2012, Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes, Diabetes Res Clin Pract, 98, 83, 10.1016/j.diabres.2012.05.002 · DOI
  27. Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129(suppl 2), S49, 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
  28. Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129(suppl 2), S1, 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  29. Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2 · DOI · Paper page
  30. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  31. Lawes, 2002, Blood pressure and coronary heart disease: a review of the evidence, Semin Vasc Med, 2, 355, 10.1055/s-2002-36765 · DOI
  32. Reboussin, 2018, Circulation, 71, e116
  33. Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404 · DOI · Paper page
  34. Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005 · DOI · Paper page
  35. Ambrosius, 2014, The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT), Clin Trials, 11, 532, 10.1177/1740774514537404 · DOI · Paper page
  36. Cushman, 2007, Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Am J Cardiol, 99, 44i, 10.1016/j.amjcard.2007.03.005 · DOI · Paper page
  37. Margolis, 2013, Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial, JAMA, 310, 46, 10.1001/jama.2013.6549 · DOI · Paper page
  38. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  39. Fihn, 2014, Circulation, 130, 1749, 10.1161/CIR.0000000000000095 · DOI · Paper page
  40. Gerhard-Herman, 2017, 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, Circulation, 135, e726, 10.1161/CIR.0000000000000471 · DOI · Paper page
  41. Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 · DOI · Paper page
  42. Bundy, 2017, Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis, JAMA Cardiol, 2, 775, 10.1001/jamacardio.2017.1421 · DOI · Paper page
  43. Fihn, 2014, Circulation, 130, 1749, 10.1161/CIR.0000000000000095 · DOI · Paper page
  44. Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies, BMJ, 338, 10.1136/bmj.b1665 · DOI · Paper page
  45. Thomopoulos, 2016, Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials, J Hypertens, 34, 613, 10.1097/HJH.0000000000000881 · DOI · Paper page
  46. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  47. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  48. Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468 · DOI · Paper page
  49. Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 · DOI · Paper page
  50. Wang, 2016, Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials, Medicine (Baltimore), 95
  51. Thompson, 2011, Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis, JAMA, 305, 913, 10.1001/jama.2011.250 · DOI · Paper page
  52. Zanchetti, 2006, Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial, J Hypertens, 24, 2163, 10.1097/01.hjh.0000249692.96488.46 · DOI · Paper page
  53. Xie, 2015, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, Lancet, 387, 435, 10.1016/S0140-6736(15)00805-3 · DOI · Paper page
  54. Lv, 2013, Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis, CMAJ, 185, 949, 10.1503/cmaj.121468 · DOI · Paper page
  55. Turnbull, 2005, Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials, Arch Intern Med, 165, 1410, 10.1001/archinte.165.12.1410 · DOI · Paper page
  56. Leenen, 2006, Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial, Hypertension, 48, 374, 10.1161/01.HYP.0000231662.77359.de · DOI · Paper page
  57. Wright, 2009, ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses, Arch Intern Med, 169, 832, 10.1001/archinternmed.2009.60 · DOI
  58. Wright, 2008, Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch Intern Med, 168, 207, 10.1001/archinternmed.2007.66 · DOI · Paper page
  59. Wright, 2015, A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939 · DOI · Paper page
  60. Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421 · DOI · Paper page
  61. Turnbull, 2008, Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials, Eur Heart J, 29, 2669, 10.1093/eurheartj/ehn427 · DOI · Paper page
  62. Turnbull, 2008, Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials, Eur Heart J, 29, 2669, 10.1093/eurheartj/ehn427 · DOI · Paper page
  63. 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
  64. Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141 · DOI · Paper page
  65. Artinian, 2010, Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association, Circulation, 122, 406, 10.1161/CIR.0b013e3181e8edf1 · DOI · Paper page
  66. Eckel, 2014, 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129(suppl 1), S76, 10.1161/01.cir.0000437740.48606.d1 · DOI · Paper page
  67. Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769 · DOI · Paper page
  68. Carter, 2009, The potency of team-based care interventions for hypertension: a meta-analysis, Arch Intern Med, 169, 1748, 10.1001/archinternmed.2009.316 · DOI · Paper page
  69. Proia, 2014, Team-based care and improved blood pressure control: a community guide systematic review, Am J Prev Med, 47, 86, 10.1016/j.amepre.2014.03.004 · DOI · Paper page
  70. Thomas, 2014, Check it, change it: a community-based, multifaceted intervention to improve blood pressure control, Circ Cardiovasc Qual Outcomes, 7, 828, 10.1161/CIRCOUTCOMES.114.001039 · DOI
  71. Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769 · DOI · Paper page
  72. Agarwal, 2011, Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis, Hypertension, 57, 29, 10.1161/HYPERTENSIONAHA.110.160911 · DOI · Paper page
  73. Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, Circulation, 124, 2458, 10.1161/CIR.0b013e318235eb4d · DOI · Paper page
  74. Fihn, 2014, Circulation, 130, 1749, 10.1161/CIR.0000000000000095 · DOI · Paper page
  75. Fihn, 2012, Circulation, 126, e354, 10.1161/CIR.0b013e318277d6a0 · DOI · Paper page
  76. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation, 128, e240, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  77. 2016, Standards of Medical Care in Diabetes–2016: Summary of Revisions, Diabetes Care, 39, S4

Cited by

See all 947

Metadata

Authors
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T.
Venue
Journal of the American Society of Hypertension
Publisher
Elsevier BV
Published
2018-08
Volume
12
Issue
8
Pages
579.e1-579.e73
ISSN
  • 1878-7436 (ISSN-L)
  • 1933-1711
OpenAlex
W3138221603
Cited by
947
References
357
FWCI
152.25
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.